comparemela.com
Latest Breaking News On - Mabwell biosciences - Page 1 : comparemela.com
Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection
Investegate announcements from Junshi Biosciences, Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection
Guangzhou
Guangdong
China
Beijing
Maryland
United-states
Shanghai
Suzhou
Jiangsu
San-francisco
California
Chinese
Junshi Biosciences Announces Approval of Supplemental
SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading.
Guangzhou
Guangdong
China
Beijing
Maryland
United-states
Shanghai
Suzhou
Jiangsu
San-francisco
California
Chinese
Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection
SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated
China
United-states
Shanghai
Chinese
Datao-liu
Junshi-bioscience
Junshi-biosciences
Zhi-li
Mabwell-biosciences
Mabwell-bioscience
Ir-team
Pr-team
vimarsana © 2020. All Rights Reserved.